New trial site, UPMC, joins GID BIO trial

New trial site, the University of Pittsburgh Medical Center, joins GID BIO's pivotal trial

Dr Peter Rubin, MD, MBA, FACS Photo

Peter Rubin, MD, MBA, FACS, Endowed Professor and Chair of Plastic Surgery at the Center for Innovation in Restorative Medicine at UPMC and the University of Pittsburgh joins as GID BIO’s latest principal investigator in a pivotal trial evaluating cellular therapy for the treatment of pain and function as a result of knee osteoarthritis. 

“This is a very important study being done in a rigorous, randomized, controlled manner with the potential to develop Level 1 evidence in support of cell therapy for musculoskeletal treatments. I have been studying cell therapy in the laboratory for many years and our team is excited about participating in this clinical trial,” noted Dr. Rubin. 

His team joins seven other trial sites across the country including Wake Forest School of Medicine, OrthoCarolina, and AdventHealth Orlando led by Neil Sparks, DO, MS, Claude T. Moorman, III, MD, and Tariq Awan, DO, respectively.

For more information about the trial, visit clinicaltrials.gov.

Our cell therapy is not approved by the FDA for sale or use in the US. 

Share the news using the buttons below
Facebook
Pinterest
Twitter
LinkedIn

Newsletter

Signup our newsletter to get updated information, and insight about GID BIO

Latest article

error: Content is protected !!
Skip to content